8-K: Doximity Reports Q3 Growth, CFO on Leave, $500M Buyback

Doximity, Inc. announced its fiscal Q3 2026 financial results with 10% revenue growth, strong user engagement, a new $500 million stock repurchase program, and a temporary medical leave for its CFO.

Summary

• Total revenues for the fiscal third quarter ended December 31, 2025, reached $185.1 million, marking a 10% increase year-over-year.
• Net income for the quarter was $61.6 million, representing a 33.3% margin, a decrease from $75.2 million (44.6% margin) in the prior year.
• Adjusted EBITDA increased by 9% year-over-year to $111.4 million, with a margin of 60.2%.
• Diluted net income per share was $0.31, down from $0.37 in the comparable prior period, while non-GAAP diluted net income per share increased to $0.46 from $0.45.
• Operating cash flow decreased by 7% to $60.9 million, and free cash flow decreased by 8% to $58.5 million.
• The company reported record engagement with over 1 million quarterly active prescribers on its newsfeed, 720,000 users on workflow products, and over 300,000 users on nascent AI products.
• Doximity's board of directors authorized a new program to repurchase up to $500 million of its Class A common stock.
• Anna Bryson, the company's Chief Financial Officer, is taking a temporary medical leave of absence, with Siddharth Sitaram appointed as interim principal financial and accounting officer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. Strong revenue growth, high Adjusted EBITDA margins, and impressive AI product adoption are significant positives. However, the decline in GAAP net income and cash flow, coupled with the CFO's temporary leave, introduce some cautionary elements.

Positives

• Revenue grew 10% year-over-year to $185.1 million, demonstrating continued top-line expansion.
• Adjusted EBITDA increased by 9% year-over-year to $111.4 million, indicating healthy operational profitability.
• Non-GAAP diluted net income per share increased to $0.46 from $0.45, showing non-GAAP earnings growth.
• Record user engagement was achieved across the platform, with over 1 million quarterly active prescribers on the newsfeed and a record jump to 720,000 users on workflow products.
• Significant adoption of new AI products, with over 300,000 users, highlights successful innovation and potential for future growth.
• The board authorized a new $500 million stock repurchase program, signaling confidence in the company's valuation and commitment to shareholder returns.

Negatives

• Net income decreased to $61.6 million (33.3% margin) from $75.2 million (44.6% margin) year-over-year, indicating a decline in GAAP profitability.
• Diluted net income per share decreased to $0.31 from $0.37 year-over-year.
• Operating cash flow decreased by 7% to $60.9 million, and free cash flow decreased by 8% to $58.5 million, suggesting reduced cash generation efficiency.
• Non-GAAP net income slightly decreased to $91.1 million from $91.4 million year-over-year.
• The Chief Financial Officer, Anna Bryson, is taking a temporary medical leave of absence, introducing an element of uncertainty in key financial leadership.

Risks

• The timing and scope of anticipated stock repurchases may not materialize as expected.
• Uncertainty in the current economic environment and broader macroeconomic conditions could impact business performance.
• Ability to retain existing members or add new members to the platform and maintain or grow their engagement.
• Ability to attract new customers or retain existing customers.
• The impact of prioritizing members' interests on financial outcomes.
• Potential breaches in security measures or unauthorized access to members' data.
• Challenges in maintaining or managing growth effectively.

Future Outlook

Doximity provided guidance for its fiscal fourth quarter ending March 31, 2026, expecting revenue between $143 million and $144 million and Adjusted EBITDA between $63.5 million and $64.5 million. For the full fiscal year ending March 31, 2026, updated guidance projects revenue between $642.5 million and $643.5 million and Adjusted EBITDA between $355.5 million and $356.5 million.

Management Comments

• "We're proud to deliver another quarter of strong profits and record engagement."
• "Our newsfeed had more than 1 million quarterly active prescribers, our workflow products had 720,000 (a record QoQ jump), and our nascent AI products had over 300,000."
• "In short, the addition of AI features across our platform has made us more useful than ever."

Industry Context

StockSavvy.ai notes that Doximity's continued revenue growth and strong user engagement, particularly the rapid adoption of AI features, position it well within the evolving digital health landscape. The company's focus on enhancing utility for medical professionals through AI aligns with broader industry trends emphasizing efficiency and advanced tools in healthcare. While competitors are also exploring AI, Doximity's established network of over 85% of U.S. physicians provides a significant competitive moat for feature adoption and data leverage.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess Doximity's performance against global benchmarks in detail. However, Doximity's 10% revenue growth is solid for a mature platform, and its 60.2% Adjusted EBITDA margin remains exceptionally high, often exceeding those of many SaaS and digital health companies, which typically range from 20-40% for profitable entities. The decline in GAAP net income and cash flow, however, warrants closer scrutiny against peers who might be managing profitability more consistently while investing in growth.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from the $500 million stock repurchase program, but mixed financial results (revenue/EBITDA growth vs. GAAP net income/cash flow decline) may lead to varied sentiment. The CFO's temporary leave introduces leadership uncertainty.
• Employees: The company's continued growth and investment in AI could signal stability and future opportunities.
• Customers (medical professionals): Enhanced platform utility through AI features and record engagement suggest improved value proposition, potentially leading to stronger retention and acquisition.
• Customers (pharmaceutical companies/hospitals): Continued growth in Doximity's network and engagement metrics indicate a robust platform for reaching medical professionals, maintaining value for advertisers and partners.

Next Steps

• Doximity will host a webcast on February 5, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results.
• The company will continue its stock repurchase program, subject to market conditions.

Key Dates

Recommendation

Doximity's Q3 results present a mixed picture. While revenue and Adjusted EBITDA growth are solid, and user engagement, particularly with AI features, is very strong, the decline in GAAP net income and cash flow is a concern. The new $500 million stock repurchase program is a positive for shareholder value. However, the temporary medical leave of the CFO introduces an element of uncertainty in financial leadership. A seasoned investor would likely 'hold' to observe how the company manages profitability trends, the impact of AI investments on the bottom line, and the stability of the interim financial leadership before making a more definitive move.

Keywords

Doximity, DOCS, Healthcare Technology, Digital Health, Medical Professionals Platform, SEC Filing, Financial Results, Earnings, Adjusted EBITDA, Stock Repurchase, CFO Leave, AI Products, User Engagement